Phar­ma's new 'Ber­lin De­c­la­ra­tion' seeks to re­serve vac­cines, ther­a­peu­tics in pro­duc­tion for low-in­come coun­tries

As Pfiz­er/BioN­Tech and Mod­er­na re­main re­luc­tant to share IP or pro­vide tech trans­fer to ex­pand the man­u­fac­ture of their life-sav­ing mR­NA vac­cines for Covid-19, the In­ter­na­tion­al Fed­er­a­tion of Phar­ma­ceu­ti­cal Man­u­fac­tur­ers & As­so­ci­a­tions on Tues­day un­veiled a new plan, build­ing off those Covid suc­cess­es, to en­sure more eq­ui­table pan­dem­ic pre­pared­ness.

The plan, known as the “Berlin De­c­la­ra­tion,” will be brought be­fore G7 and G20 coun­tries soon and pro­pos­es to re­serve an al­lo­ca­tion of the re­al-time pro­duc­tion of drugs, vac­cines and di­ag­nos­tics for dis­tri­b­u­tion to pri­or­i­ty pop­u­la­tions in low­er in­come coun­tries, as de­ter­mined by health au­thor­i­ties dur­ing pan­demics.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.